No abstract

No abstract

No abstract

No abstract

Background There are many surgical approaches which described extent of resection of the colon for adequate surgical management of splenic flexure cancer, but up till now there is no established surgical procedure, this is because the presence of double lymphatic drainage of the mesenteric vessels. Segmental resection of the colon for the management of splenic flexure cancer was a recently accepted surgical procedure. Objective In the present study, we aimed to compare three surgical management techniques to clarify the best management approach of Egyptian patients with splenic flexure cancer regarding operative, clinical, and oncological outcomes: segmental resection, and extended left or right hemicolectomy,. Materials and Methods In the present study, we included 90 patients with splenic flexure cancer. Cases were divided into 3 groups. Each group included 30 patients in order to compare three surgical techniques: segmental resection, extended left hemicolectomy, and extended right hemicolectomy. Results We have found no statistically significant differences between the three included groups regarding operative findings, postoperative complications, local recurrence, distant recurrence, disease progression, recurrence-free survival rate, progression-free survival rate, and overall survival rate. The operative time was longer, and the number of lymph nodes was higher in the extended right hemicolectomy group (p < 0.001). Conclusion We have shown that segmental resection of the splenic flexure is surgically and clinically suitable for the adequate management of operable cases of carcinoma of the splenic flexure.

No abstract

No abstract

Background: Diffuse large B-cell lymphoma (DLBCL); the commonest subtype of NHL, is genetically, biologically and clinically heterogeneous disorder which is potentially curable with combination chemoimmunotherapy, however, Prognostic assessment is important for tailoring therapy. Beclin-1, a mammalian ortholog of the yeast autophagyrelated gene 6 protein, and important mediator of autophagy was found to predict clinical outcomes in many cancer patients. Methods: This prospective cohort study was carried out at medical oncology department, Zagazig University and Health insurance hospitals and included 32 patients with CD20 positive de novo DLBCL, they were subjected to routine clinical and laboratory assessment with immunohistochemical analysis for beclin-1 status which further divided the patients into 2 groups of high and low beclin-1,Patients received first line therapy with R-CHOP regimen, then assessed for therapy response and followed up after treatment for estimating overall (OS) and disease free survival (DFS). Results: High Beclin-1 expression was found in 12 patients (37.5%) and it wasn't associated with significant correlation with clinic-demographic patient characteristics. The Complete remission rate was 59.4% and beclin-1 expression didn't significantly affect clinical outcome, except for the significant death rate (p= 0.02). The 3-year OS and DFS were 78.1% and 45.0% respectively and high beclin-1 was significantly associated with better OS (by multivariate analysis) but not DFS. Conclusions: Beclin-1 didn't provide a prognostic indicator for response to treatment. However, it's found to be independent predictor for OS in DLBCL patients.